Back to Search
Start Over
Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices.
- Source :
-
Clinical journal of oncology nursing [Clin J Oncol Nurs] 2024 Sep 17; Vol. 28 (5), pp. 1-8. - Publication Year :
- 2024
-
Abstract
- Background: Amivantamab is an epidermal growth factor receptor (EGFR) and MET bispecific antibody approved for certain patients with advanced non-small cell lung cancer with EGFR variant. Cutaneous toxicities are known on-target effects of EGFR inhibition.<br />Objectives: This article describes the occurrence and management of cutaneous toxicities in patients whose disease progressed on platinum chemotherapy treated with amivantamab.<br />Methods: Post hoc analysis evaluated incidence, severity, and time to first onset of rash and paronychia. Five nurses and advanced practice providers were interviewed.<br />Findings: Of 380 patients, 296 (78%) experienced treatment-related rash and/or paronychia. Paronychia (43%), rash (36%), and dermatitis acneiform (35%) were most frequent, with scalp rash reported by 17%. Treatment modifications because of rash and paronychia were infrequent. Nurses and advanced practice providers collaborate with physicians to manage cutaneous toxicities by administering comedications, modifying amivantamab dose, and educating patients.
- Subjects :
- Humans
Female
Middle Aged
Male
Aged
Adult
Aged, 80 and over
Paronychia chemically induced
Paronychia drug therapy
Antineoplastic Agents adverse effects
Antineoplastic Agents therapeutic use
Practice Guidelines as Topic
Drug Eruptions etiology
Carcinoma, Non-Small-Cell Lung drug therapy
Lung Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1538-067X
- Volume :
- 28
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Clinical journal of oncology nursing
- Publication Type :
- Academic Journal
- Accession number :
- 39324708
- Full Text :
- https://doi.org/10.1188/24.CJON.1-8.AP